Similar articles

• Postmortem studies of peptides in Alzheimer's disease and Huntington's disease.

  Rossor M, Emson P, Dawbarn D, Dockray G, Mountjoy C, Roth M. Rossor M, et al. Res Publ Assoc Res Nerv Ment Dis. 1986;64:259-77. Res Publ Assoc Res Nerv Ment Dis. 1986. PMID: 2425405 Review. No abstract available.
• Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation.

  Freeman W, Morton AJ. Freeman W, et al. Brain Res Bull. 2004 Mar 1;63(1):45-55. doi: 10.1016/j.brainresbull.2003.12.004. Brain Res Bull. 2004. PMID: 15121238
• Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders: evidence from CSF and post-mortem studies.

  Nemeroff CB, Bissette G. Nemeroff CB, et al. Prog Clin Biol Res. 1985;192:333-41. Prog Clin Biol Res. 1985. PMID: 2934745
• Expression of Fos, Jun, and Krox family proteins in Alzheimer's disease.

  MacGibbon GA, Lawlor PA, Walton M, Sirimanne E, Faull RL, Synek B, Mee E, Connor B, Dragunow M. MacGibbon GA, et al. Exp Neurol. 1997 Oct;147(2):316-32. doi: 10.1006/exnr.1997.6600. Exp Neurol. 1997. PMID: 9344557
• [Approach to the dementia research].

  Tomonaga M. Tomonaga M. Rinsho Shinkeigaku. 1989 Dec;29(12):1532-5. Rinsho Shinkeigaku. 1989. PMID: 2698299 Review. Japanese.